JWJoanne G. Wildenbeest

Joanne G. Wildenbeest

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joanne G. Wildenbeest has a total of 244 co-authors. Here are the top co-authors by number of shared publications:

  • Louis J. Bont

    Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children's Hospital, University Medical Center Utrecht, Lundlaan 6, 3584 EA Utrecht, The Netherlands

    7 shared publications
  • Louis J. Bont

    Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

    7 shared publications
  • Emily W. E. M. Phijffer

    Department of Pediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital, University Medical Center Utrecht, Utrecht, The Netherlands

    5 shared publications
  • Louis J Bont

    Department of Paediatric Infectious Diseases and Immunology, Wilhelmina Children’s Hospital/University Medical Center Utrecht , Utrecht

    5 shared publications
  • Christopher Collett Butler

    Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

    4 shared publications
  • Dirk Eggink

    Centre for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands

    4 shared publications

Latest Publications

  • Open Access

    Placental Histopathology and Transplacental Transfer of RSV-specific Neutralizing Antibodies The Silver Study

    by Emily W. E. M. Phijffer, Joukje Willemsen, Joanne G. Wildenbeest, Larry J. Anderson, Kitty W. M. Bloemenkamp, Floris Groenendaal, Peter G. J. Nikkels, Louis J. Bont

    Background: Maternally acquired passive immunity via transplacental antibody transport is crucial for the protection of infants against infectious diseases in early life. We examined whether placental histological characteristics impact the transplacental transfer of natural respiratory syncytial virus (RSV)-specific neutralizing antibodies. Methods: We performed a prospective, observational, cross-sectional study. Pregnant women were enrolled with a 1:1:1 inclusion ratio of extremely preterm-born infants (24–32 weeks), moderately preterm-born infants (33–36 weeks) and term-born infants (37–42 weeks). Cord–maternal ratios (CMRs) for serum neutralizing RSV-A and -B antibodies were analyzed in relation to 16 placental histologic characteristics. Results: In total, 85 mother–infant pairs were available for analysis. Infant gestational age was significantly correlated with CMRs for RSV-A and -B specific antibodies ( B = 0.10, P < 0.001). Although a few placental characteristics showed a univariate association with CMR, the multivariate model showed that only gestational age was independently related to CMR ( B = 0.11, P < 0.001). Conclusions: Our study confirms that CMRs increase during gestation. However, variations in placental histology may not affect transplacental RSV-A and RSV-B antibody transfer. We hypothesize that the placental compensatory capacity and active transport mechanism may play a key role in transplacental antibody transfer.

  • Open Access

    Low Cord Blood Titers Are Associated With Prolonged Maternal Respiratory Syncytial Virus Antibody Half-Lives in Preterm Infants

    by Joukje E Willemsen, Emily W E M Phijffer, Joanne G Wildenbeest, Larry J Anderson, Binh Ha, Ranjini Sankaranarayanan, Floris Groenendaal, Kitty W M Bloemenkamp, José A M Borghans, Julia Drylewicz, et al.

    Background: Preterm infants are at higher risk of severe respiratory syncytial virus (RSV) infection, partially because of reduced placental transfer of maternal antibodies (Abs). Increased risk of severe infection persists in the first year of life. This study evaluates the postnatal kinetics of RSV-neutralizing Abs in preterm and full-term infants born to unvaccinated mothers. Methods: We enrolled infants with a gestational age (GA) of 24–42 weeks born in hospital from RSV-unvaccinated mothers. Serum was collected at birth (cord blood), 1–2 weeks, and 4–8 weeks. Linear mixed-effects models were used to estimate half-lives of RSV-neutralizing Abs in relation to GA and cord blood titer. Analyses were repeated for total serum immunoglobulin G1 (IgG1) to confirm the robustness of our findings. Results: Of 169 infants, 95 were born preterm (<37 weeks GA, including 53 neonates <32 weeks GA). Premature birth was related to prolonged half-life of RSV-neutralizing Abs (approximately 79 days very preterm to approximately 30 days in term infants). The inverse association between GA and Ab half-life was largely accounted for by an inverse association between cord blood Ab levels and Ab half-life. A doubling in cord blood titers led to a reduction in half-life of approximately 20% for RSV-neutralizing Abs and approximately 32% for IgG1. Conclusions: Postnatal Ab half-life depends on starting levels: higher titers decline faster. If our observation would be replicated for vaccine-induced Abs, the difference in vaccine protection between preterm and term infants may be smaller than anticipated.

  • Open Access

    Preferences of Dutch pregnant women for RSV immunisation – a mixed method study

    by Emily W.E.M. Phijffer, Charuja Sivakumar, Agnes van Den Hoogen, Neeltje M.T.H. Crombag, Marieke C. Punt, Louis J. Bont, Kitty W.M. Bloemenkamp, Joanne G. Wildenbeest


  • Open Access

    Normalization of Seasonality and Age Distribution of Pediatric RSV Infection Following the Pandemic Disruption in the Netherlands

    by Neele Rave, Marit E M de Bruijne, Rebecca K Stellato, Michiel A G E Bannier, Daniel M Weinberger, Yvette N Löwensteyn, Joanne G Wildenbeest, Louis J Bont, Marlies Vermaas—Van Putten

    Background: The COVID-19 pandemic caused a global disruption in respiratory syncytial virus (RSV) epidemiology. However, data on RSV epidemiology in the postpandemic period remain limited. We analyzed shifts in RSV seasonality, age distribution, and disease severity among RSV-positive children in the Netherlands before, during, and after the pandemic. Methods: Between May 2021 and April 2024, children under two years of age, admitted with RSV to 47 Dutch hospitals were included in a prospective surveillance study. We compared demographic and clinical characteristics of RSV-positive patients with data from the pre-COVID period (2018–2020), the COVID period and the post-COVID period (2022–2024). Results: A total of 8457 RSV-positive cases were included, with detailed data collected from 2708 patients (13 hospitals). Following an unusual off-season shift and a period of endemic circulation, RSV seasonality has reverted to its typical prepandemic winter pattern. The median age at admission increased from 2.2 months (interquartile range [IQR]: 1.1–5.6) in the prepandemic period to 4.9 months (IQR 1.8–11.4, P < .05) during the summer outbreak (2021). This subsequently returned to prepandemic median age in the winter of 2023/2024 (2.7 months, IQR 1.3–8.0, not significant). We observed no differences in the prevalence of preterm birth or comorbidities among RSV-positive children before, during or after the COVID pandemic. Conclusions: The COVID-19 pandemic profoundly disrupted RSV epidemiology. This prospective study demonstrates a rapid re-establishment of prepandemic patterns, including a return toward the typical age distribution during early childhood.


  • Antibody concentration and function following SARS-CoV-2 vaccination decrease with age in adults and children with Down syndrome

    by Bianca M.M. Streng, Lobke C.M. Hensen, Eveline M. Delemarre, Rob S. Binnendijk, Gaby Smits, Gerco Den Hartog, Fiona R. van der Klis, Esther de Vries, Judith A. Burger, Marit J. van Gils, et al.


  • Open Access

    Impact of RSV hospitalization on healthcare costs, caregivers’ productivity loss, and quality of life in children ≤ 2 years old in five European countries

    by Joanne G. Wildenbeest, Louis Bont, Daniela Cianci, Geert W. J. Frederix, Cristina Calvo, Johannes Liese, Renato Cutrera, Chiara Azzari, Jacques Brouard, Federico Martinon-Torres, et al.

    Respiratory syncytial virus (RSV) is a leading cause of hospitalizations in young children globally. We evaluated direct medical costs, caregiver work loss, and child quality of life (QoL) impairment associated with RSV hospitalization. Children ≤ 2 years with laboratory-confirmed RSV infection were prospectively identified between October 2020 and May 2023 at ten hospitals in Germany, Spain, Italy, France, and England. Direct costs were calculated based on country-specific unit costs per hospital day. Productivity loss and QoL impairment were ascertained by two validated, caregiver-administered instruments: 1) Work Productivity and Activity Impairment Questionnaire: Child’s Hospitalization for Respiratory Illness (WPAI:CHRI), administered before discharge and 2) TNO AZL Child Quality of Life (TAPQOL), administered at baseline (shortly after admission) and before discharge. Among 382 hospitalized children, 261 (69%) were < 6 months and 306 (80%) were previously healthy. Median length of stay was 6 days (Interquartile Range (IQR) 4–8) and 50 (13%) were admitted to Paediatric Intensive Care Unit (PICU). Median hospital costs/admission were €4,266 (IQR 2,438–8,442), substantially varying by country (range €2,377-€8,541). Productivity loss was substantial with 129/211 (61%) employed caregivers reporting lost work-hours (mean 30.5 ± 18/admission). Child QoL was significantly reduced during RSV hospitalization in most domains, with the highest QoL impairment observed in the lung domain (mean difference 34.2 out of 100 [95% CI 30–38.4]. Conclusion: RSV hospitalization in children ≤ 2 years was associated with significant costs and QoL impairment in five European countries, emphasizing the importance of preventing severe RSV disease. What is known: • RSV is a major cause of hospitalization in young children under 5 years of age globally. • Most hospitalized children with RSV are previously healthy. What is new: • RSV hospitalization in children ≤2 years was associated with significant costs in Europe, with median hospital costs per admission at €4,266, substantial varying by country (range: €2,377 - €8,541). • Caregivers of children ≤ 2 years hospitalized with RSV reported substantial productivity loss and a reduction in the quality of life of their child during hospitalization, as measured using validated instruments (WPAI-CHRI and TAPQOL).


  • Open Access

    Clinical and Socioeconomic Burden of RSV Infections Among Older Adults in Primary Care: An International Prospective Cohort Study

    by Sarah F. Hak, Joanne G. Wildenbeest, Sara Bracaloni, Michela Scarpaci, Tommaso Cosci, Enrica Esposito, Maria Chironna, Donatella Panatto, Giancarlo Icardi, Melissa Torrisi, et al.

    Introduction: Respiratory syncytial virus (RSV) is increasingly recognized as an important cause of acute respiratory infections (ARI) in older adults. However, primary care data on RSV infections are scarce. Methods: We conducted a prospective cohort study over two winter seasons (2022–2023 and 2023–2024) in Italy and the Netherlands (NCT06318936). Older adults (≥ 60 years) presenting to primary care with ARI were tested for RSV and influenza. Clinical and socioeconomic burden was assessed through questionnaires on Days 1, 14, and 30. In secondary analyses, we compared between RSV‐ and influenza‐positive patients and estimated RSV‐ARI incidence in Dutch primary care. Results: Of 703 older adults tested, 93 (13.2%) were RSV‐positive and 100 (14.2%) influenza‐positive. In RSV patients (mean age: 76 years [SD: 8], 63% ≥ 1 comorbidity), mean illness duration was 17 days (SD: 10). Repeat primary care visits occurred in 38% (33/87), emergency department referral in 5% (4/88), and hospitalization in 2% (2/88) of RSV patients. The mean costs per RSV episode were €78.1 (95%CI: 74.4–81.8) and €279.7 (95%CI: 245.5–318.2) from a healthcare system and societal perspective, respectively. The annual RSV‐ARI incidence rate was 10.3 episodes per 1000 person‐years. RSV patients were significantly older, and had less often fever, muscle pain, and fatigue than influenza patients, but clinical and socioeconomic burdens were comparable. Conclusions: This prospective study is the first sufficiently large to demonstrate that the primary care burden of RSV infections among older adults is substantial and comparable with influenza. These findings are highly relevant for informing public health decisions on novel RSV vaccines.


  • Open Access

    Dynamics of RSV hospitalization rates in ≤ 2-year-old children between 2020–2023 in Europe

    by Joanne G. Wildenbeest, Louis Bont, Daniela Cianci, Chiara Azzari, Jacques Brouard, Cristina Calvo, Renato Cutrera, Simon B. Drysdale, Ralph Epaud, Atul Gupta, et al.

    With the newly approved RSV preventive strategies enabling universal protection of infants, it is crucial to gain a comprehensive understanding of RSV hosp


  • Open Access

    Antibiotic use attributable to RSV infections during infancy—an international prospective birth cohort study

    by Sarah F Hak, Roderick P Venekamp, Marie-Noëlle Billard, Daniela Cianci, Marlies A Van Houten, Andrew J Pollard, Terho Heikkinen, Steve Cunningham, Federico Martinon-Torres, Ana Dacosta-Urbieta, et al.

    Background: Early-life antibiotic use impacts microbiome composition and contributes to the emergence of antimicrobial resistance. Despite respiratory syncytial virus (RSV) being a leading cause of acute respiratory infections (ARI), accurate estimates of antibiotic use attributable to RSV are lacking. Objectives: To assess RSV-associated antibiotic use during the first year of life. Patients and methods: The RESCEU birth cohort study followed healthy term infants, born (n = 9154) between 1 July 2017 and 31 July 2020 from five European countries, to identify RSV-ARI hospitalizations during infancy. In a nested cohort (n = 993), we performed active RSV surveillance by collecting nasal swabs in case of ARI symptoms during RSV seasons (October–April). Antibiotic use during hospitalization was identified through chart review, while outpatient data were collected via parental questionnaires. Results: In the total cohort, antibiotics were used in 22.8% of RSV hospitalizations (33/145) and 62.5% of RSV intensive care admissions (5/8). In the nested cohort, antibiotics were used in 5.2% of any-severity RSV-ARI (13/250) and 9.9% of medically attended RSV-ARI (13/131). This results in an estimated incidence of 1.3% (95%CI: 0.8–2.0) of healthy term infants receiving ≥1 course of antibiotics associated with RSV infection in their first year, with an incidence rate of 1.1 RSV-associated antibiotic prescriptions per 1000 infant-months (95%CI: 0.6–1.9). As such, RSV accounts for 22.9% of antibiotic prescriptions for ARI during RSV seasons. Conclusions: One in 77 healthy term infants receives antibiotics during RSV infection before their first birthday. Real-world evidence is needed to establish the impact of RSV immunization on antibiotic use during infancy. Clinical Trials Registration: NCT03627572.


  • Open Access

    Impact of co-infection with SARS-CoV-2 and other respiratory viruses on illness: Pooled analyses of 11 COVID-19 cohorts

    by Marieke L.A. de Hoog, Emma S.E.M. Hauser - van Westrhenen, Angelique M.A.M. Winkel, Menno D. de Jong, Marlies A. van Houten, Steven F.L. van Lelyveld, Dirk Eggink, Sjoerd Euser, Liesbeth Duijts, Joanne G. Wildenbeest, et al.